硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展

覃金玲; 孙德友; 丁明和; 刘蔚; 范彦博; 夏军

doi:10.3969/j.issn.1006-0111.2017.03.004

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展

覃金玲, 孙德友, 丁明和, 刘蔚, 范彦博, 夏军

文章导航 > 药学实践与服务 > 2017 > 35(3): 205-207,274

覃金玲, 孙德友, 丁明和, 刘蔚, 范彦博, 夏军. 硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展[J]. 药学实践与服务, 2017, 35(3): 205-207,274. doi: 10.3969/j.issn.1006-0111.2017.03.004

引用本文:

QIN Jinling, SUN Deyou, DING Minghe, LIU Wei, FAN Yanbo, XIA Jun. Progress in research of sodium prasterone sulfate in vaginal atrophy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 205-207,274. doi: 10.3969/j.issn.1006-0111.2017.03.004

Citation:

QIN Jinling, SUN Deyou, DING Minghe, LIU Wei, FAN Yanbo, XIA Jun. Progress in research of sodium prasterone sulfate in vaginal atrophy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 205-207,274. doi: 10.3969/j.issn.1006-0111.2017.03.004

硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.004

马应龙药业集团股份有限公司, 湖北武汉 430064

Progress in research of sodium prasterone sulfate in vaginal atrophy

Mayinglong Pharmaceutical Group Co.Ltd., Wuhan 430064, China

摘要: 硫酸普拉睾酮钠（dehydroepiandrosterone sulfate， sodium prasterone sulfate， DHEAS）和普拉睾酮（dehydroepiandrosterone，prasterone，DHEA）是人体肾上腺合成分泌的内源性物质，亦是转化为甾体激素包括性激素的前体。按照胞内分泌学说，绝经后女性大多数会产生由于缺乏DHEAS或DHEA引起的内源性性激素缺乏而导致的阴道萎缩性疾病，因此适度补充DHEAS能缓解阴道萎缩的相关症状。多项临床研究表明，DHEAS能有效缓解阴道萎缩的相关症状，长期使用后患者体内的雄激素和雌激素水平仍可维持在正常的生理浓度范围内，因此DHEAS可能会成为未来治疗阴道萎缩症的临床首选药物。
- 普拉睾酮 /
- 硫酸普拉睾酮钠 /
- 阴道萎缩
Abstract: Sodium prasterone sulfate (DHEAS) and dehydroepiandrosterone (DHEA) are endogenous steroid compounds, which are synthesized and secreted by adrenal gland. They are the precursors of steroid hormones,including sex hormone. Based on intracrine theory,the majority of postmenopausal women will have vaginal atrophy,which is caused by the absence of endogenous hormones,DHEAS or DHEA. Moderate supplementation of DHEAS can relieve the associated symptoms of vaginal atrophy.Many clinical researches have demonstrated that DHEAS can efficiently alleviate the related symptoms of vaginal atrophy.The concentration of androgen and estrogen in patients with long term use of DHEAS are still in the normal intracrine physiological range. Therefore,DHEAS may become the first drug for the treatment of vaginal atrophy in the future.
- dehydroepiandrosterone /
- sodium prasterone sulfate /
- vaginal atrophy

[1]	"dehydroepiandrosterone,vaginal atrophy" [DB/OL]. Available: https://clinicaltrials.gov/ct2/results?term=vaginal+atrophy&Search=Search.
[2]	牛治欣. 阴道萎缩的诊断及治疗进展[J]. 职业与健康, 2007,23(17):1557-1558.
[3]	刘晓霞. 女性围绝经期健康大讲堂(之十三) 女性更年期泌尿生殖系统疾病治疗组合方案[J]. 首都医药, 2012:51-52.
[4]	van Geelen JM, van de Weifer PH, Amolds HT. Urogenital symptoms and resulting discomfort in non-institutionalixed Dutch women aged 50-75 years[J]. Iht Urogynecol J Pelvic Floor Dysfunct, 2000,11(1):9-14.
[5]	曹江霞,周燕. 不同分娩方式对围绝经期女性盆底功能影响的研究[J]. 中国妇幼保健, 2010,25(16):4504-4506.
[6]	王俊玲.女性更年期泌尿生殖系统症状的激素替代治疗研究[J/OL]. 心理医生,2012(5): 110-111. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_xlys-xbyb201205112.
[7]	王丽鸽,崔丽霞. 普罗雌烯治疗绝经后妇女萎缩性阴道炎的有效性及安全性的临床评估[J]. 中国妇幼保健,2007,22(13):1849-1850.
[8]	Labrie F, Luu-The V, Bélanger A, et al. Is dehydroepiandrosterone a hormone?[J]. J Endocrinol, 2005,187(2):169-196.
[9]	Labrie F, Bé langer A, Luu-The V, et al.DHEA and the intracrine formation of androgens an estrogens in peripheral target tissues: its role during aging[J]. Steroids,1998,63(5-6):322-328.
[10]	Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women[J]. J Clin Endocrinol Metab, 1997,82 (10):3498-3505.
[11]	Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women[J]. J Steroid Biochem Mol Biol, 2008,111(3-5):178-194.
[12]	Ke Y, Labrie F, Gonthier R, et al. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration[J]. J Steroid Biochem Mol Biol, 2015,154:186-196.
[13]	Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy[J]. J Sex Med, 2015,12(12):2401-2412.
[14]	Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause[J]. Menopause, 2016,23(3):243-256.
[15]	Labrie F, Montesino M, Archer DF, et al. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner[J]. Climacteric, 2015,18(6):817-825.

点击查看大图

计量

文章访问数: 3701
HTML全文浏览量: 564
PDF下载量: 1647
被引次数: 0

硫酸普拉睾酮钠治疗阴道萎缩的临床研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.004

马应龙药业集团股份有限公司, 湖北武汉 430064

收稿日期: 2016-05-24
修回日期: 2016-11-04

关键词:

普拉睾酮 /

硫酸普拉睾酮钠 /

阴道萎缩

摘要: 硫酸普拉睾酮钠（dehydroepiandrosterone sulfate， sodium prasterone sulfate， DHEAS）和普拉睾酮（dehydroepiandrosterone，prasterone，DHEA）是人体肾上腺合成分泌的内源性物质，亦是转化为甾体激素包括性激素的前体。按照胞内分泌学说，绝经后女性大多数会产生由于缺乏DHEAS或DHEA引起的内源性性激素缺乏而导致的阴道萎缩性疾病，因此适度补充DHEAS能缓解阴道萎缩的相关症状。多项临床研究表明，DHEAS能有效缓解阴道萎缩的相关症状，长期使用后患者体内的雄激素和雌激素水平仍可维持在正常的生理浓度范围内，因此DHEAS可能会成为未来治疗阴道萎缩症的临床首选药物。